哮喘相关生物标志物的研究进展  

Advances in Asthma-Related Biomarkers

作　　者：廖明月 李建保[1] 

机构地区：[1]成都中医药大学临床医学院,四川 成都

出　　处：《亚洲急诊医学病例研究》2025年第1期33-43,共11页Asian Case Reports in Emergency Medicine

摘　　要：哮喘异质性强,随着对哮喘机制与治疗手段的认识要求提高,现有的哮喘诊断体系亟需随之更新。生物标志物是可以反映生理、病理机制与治疗效果的指标,理想的生物标志物应具有敏感性、特异性,能够提供阳性和阴性预测值,同时测量简单且具有成本效益。目前已有许多着眼于哮喘生物标志物的研究,但尚未获得更多经过验证可供于投入临床的生物标志物。本文就典型与新兴哮喘诊断相关生物标志物的研究进展进行综述。Asthma is highly heterogeneous, and as the understanding of asthma mechanisms and therapeutic means increases, there is an urgent need to update the existing asthma diagnostic system accordingly. Biomarkers are indicators of physiologic and pathologic mechanisms and therapeutic efficacy. Ideally, biomarkers should be sensitive, specific, providing positive and negative predictive values, and be simple and cost-effective to measure. There have been many studies focusing on asthma biomarkers, but more validated biomarkers are not yet available. This article provides a review of the progress of research on typical and emerging biomarkers relevant to asthma diagnosis.

关 键 词：哮喘 诊断 生物标志物 

分 类 号：R56[医药卫生—呼吸系统]